Abstract: The present invention relates generally to a method of modulating graft functionality. More specifically, the present invention relates to a method of downregulating the onset or progression of graft dysfunction by downregulating the functional level of activin. The method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by graft dysfunction, such as the primary graft dysfunction associated with organ transplantation.
Type:
Application
Filed:
May 17, 2013
Publication date:
January 22, 2015
Applicant:
PARANTA BIOSCIENCES LIMITED
Inventors:
David De Kretser, Robyn O'Hehir, Yi Chen
Abstract: The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.
Type:
Application
Filed:
July 3, 2012
Publication date:
August 7, 2014
Inventors:
Craig Boyle, William Greenlee, Samuel Chackalamannil, Claire Lankin
Abstract: An inhibitor of FXII/FXIIa for the prevention of the formation and/or stabilization of thrombi during and/or after a medical procedure performed on a human or animal subject comprising contacting blood of said human or animal subject with artificial surfaces, wherein said inhibitor of FXII/FXIIa is administered before and/or during and/or after said medical procedure.
Type:
Application
Filed:
March 9, 2012
Publication date:
March 13, 2014
Inventors:
Stefan Zeitler, Marc Nolte, Stafan Schulte, Gerhard Dickneite, Ingo Pragst
Abstract: The present invention provides methods and compositions for modulating certain metabolic processes and for treating a variety of disorders associated with metabolic syndrome, including insulin related disorders, ischemia, oxidative stress, atherosclerosis, hypertension, obesity, abnormal lipid metabolism, and stroke by administering an effective dose of a chloroquine compound. The invention also provides methods and compositions relating to administering an effective dose of a chloroquine compound in combination with at least a second pharmaceutically active ingredient or compound including an antihyperglycemic diabetes treatment, an antihypertensive agent, an antithrombotic agent, and/or an inhibitor of cholesterol synthesis or absorption.
Type:
Application
Filed:
March 14, 2013
Publication date:
November 7, 2013
Inventors:
Michael B. Kastan, Clay F. Semenkovich, Jochen Schneider
Abstract: The present invention relates to a chimeric hirudin protein comprising a carrier attached to the N-terminus of hirudin, with an intervening plasmin cleavage site. The chimeric hirudin protein contains a relatively inactive form of hirudin. However, when such chimeric hirudin protein being cleaved by plasmin in the vicinity of a clot and, ultimately causing the release of active hirudin and the reduction of the size of the clot. The chimeric hirudin protein exhibited much slower clearance in mice than unfused wild-type hirudin.
Abstract: Invented is a method of treating thrombocytopenia in a human, in need thereof which comprises the in vivo administration of a therapeutically effective amount of a peptide or a non-peptide TPO receptor agonist and an anti-clotting agent or agents, and optional further active ingredients, to such human.
Type:
Grant
Filed:
May 6, 2010
Date of Patent:
July 2, 2013
Assignee:
GlaxoSmithKline LLC
Inventors:
Connie L. Erickson-Miller, Michael Arning
Abstract: A chimeric protein containing neutrophil inhibitory factor and hirugen, the chimeric protein having an amino acid sequence that includes FPRPGSGG (SEQ ID NO:21) Also provided is a pharmaceutical composition comprising the chimeric protein, which can be used for treating or preventing cerebral injury and cerebral edema, or for inhibiting platelet aggregation.
Type:
Grant
Filed:
February 18, 2008
Date of Patent:
January 29, 2013
Assignees:
Lunan Pharmaceutical Group Corporation, Fagen Biomedical Inc. Chongqing
Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with venous thrombosis. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
Type:
Application
Filed:
October 11, 2011
Publication date:
October 18, 2012
Applicants:
Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL), CELERA CORPORATION
Inventors:
Lance BARE, James J. DEVLIN, Frits R. ROSENDAAL, Pieter H. REITSMA, Irene D. BEZEMER
Abstract: A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding.
Type:
Application
Filed:
August 12, 2011
Publication date:
June 7, 2012
Inventors:
Lisa Ruderman Chen, Simon Skerjanec, Dawn Bell, Jayne Prats, Meredith Todd
Abstract: Invented is a method of treating thrombocytopenia in a human, in need thereof which comprises the in vivo administration of a therapeutically effective amount of a peptide or a non-peptide TPO receptor agonist and an anti-clotting agent or agents, and optional further active ingredients, to such human.
Type:
Application
Filed:
May 6, 2010
Publication date:
March 1, 2012
Applicant:
Glaxosmithkline LLC
Inventors:
Connie L. Erickson-Miller, Michael Arning